资源描述
*01*2023 6 14 ADC PD-1/PD-L1*PD-1/PD-L1 K 2022 200 PD-1/PD-L1 PD-1 PD-1 BMS PD-1/PD-L1 PD-1/PD-L1 PD-1/PD-L1 III PD-1/PD-L1 ADC ADC PD-1/PD-L1 ADC ADC PD-1/PD-L1 PD-1/PD-L1 ADC 2020 PD-1/PD-L1 ADC PD-1/PD-L1 PD-1/PD-L1 PD-1/PD-L1 ADC 1YWBYzQrMtQrQpRsRqNsNqR9P8QaQnPpPtRmPeRmMrPjMrQnQ8OnNwPvPrQnPMYnPoP*C O N T E N T SPD-1/PD-L1 4 PD-1 02PD-1/PD-L1 ADC 03PD-1/PD-L1 01042*PD-1/PD-L1 01.3*4 K 200 01 PD-1/PD-L1 K 2022 200 150300250350200400050100317.739.039.1(38.4%)57.5(56.5%)209.4(58.4%)201771.7(44.4%)75.6(46.8%)2018224.5110.8(49.4%)80.1(35.7%)79.2(29.1%)35.9202028.7161.720.4171.9(54.1%)143.8(52.8%)202182.5(23.0%)27.82022358.785.8(27.0%)24.12019101.7272.1+59.0%+38.9%+21.2%+16.7%+12.9%KeytrudaBMS Opdivo Tecentriq Imfinzi PD-1/PD-L1*5015020035025050010055004007003006504506003723292018Q3691022019Q313182021Q1129167137421232023Q1 2022Q4351812423164932018Q4 2019Q1 2019Q2362021Q3156322019Q412464342020Q116850292020Q2101113982020Q326321042020Q41001092322114176932021Q22010151161816014117892021Q4241372173121191002022Q128129278897181202022Q2332241393610926232022Q327138988576203712537108811642422387112375390 3874936045935125366705056135 K 01 PDB 2018 PD-1/PD-L1 2022 Q4 K-BMS-AZ-MSD-Roche-PD-1/PD-L1 PDB PDB*41%10%16%59%10%43%11%17%5%9%69%39%25%25%30%3%11%15%21%16%42%34%18%32%33%32%28%32%12%8%13%22%26%27%26%23%29%24%19%33%10%8%8%6%4%27%27%5%28%27%24%26%23%24%22%25%27%27%5%4%5%21%22%14%4%5%18%16%15%13%27%16%17%17%18%5%5%5%7%6%24%21%19%20%5%5%5%6%0%10%20%30%40%50%60%70%80%90%100%2018Q3 2019Q22%3%2018Q44%132019Q1 2019Q33%3%2023Q1 2019Q4 2020Q1 2020Q222020Q3 2020Q43%4932022Q15052021Q16702021Q22%2021Q3 2022Q3 2021Q4 2022Q22%5932022Q4387 23 613 37 87 93 112 512 2244%375 390 604 536100%3%3%3%3%3%3%4%4%3%4%6 K 01 PDB 2022 22Q3 23Q1 25%K BMS-MSD-AZ-Roche-PD-1/PD-L1 PDB%PDB*PD-1/PD-L1 4 PD-1 02.7*8 PD-1 02 PD-1 3/6 2018.12.21 2021.02.10/2021.04.13 12 2021.11.24 2022.05.13 2022.09.19(EGFR)(ALK)(NSCLC)5/6 2018.12.24 2021.02.02(nsqNSCLC)2021.06.03(sqNSCLC)2021.06.25/2022.06.24+G/GEJ 2023.05.09 EGFR-TKI EGFR NSCLC 8/9 2019.05.29 2020.03.05/2020.06.22 2020.06.22 EGFR ALK NSCLC 2021.04.29 2021.06.10 2021.12.08 2021.12.08 EGFR ALK NSCLC 2023.01.31 9/10 2019.12.26 2020.04.13 PD-L1 12 2021.01.22 2021.06.22 EGFR ALK 2021.06.22(HCC)/2022.01.05(NSCLC)MSI-H dMMR 2022.03.11 MSI-H dMMR 2022.04.13 ESCC 2022.06.10/2023.02.24 PD-L1 G/GEJ 2023.05.23 ESCC PD-1 1/2*9 PD-1 PD-1 02 PD-1 2018.06.15 EGFR ALK NSCLC 2019.10.15 PD-L1 PD-L1 1%SCCHN 2020.03.12 2021.06.10 2021.08.25 2022.06.24 CRT 2022.06.24 2023.01.17 4 cm NSCLC PD-L1 2023.01.19 UC 2018.07.20 2019.04.02 EGFR ALK(NSCLC)2019.10.02 CFDA PD-L1 TPS 1%EGFR ALK 2019.11.26 2020.06.22 PD-L1 CPS 10 ESCC 2020.12.11 PD-L1 CPS 20 HNSCC MSI-H dMMR 2021.06.10 KRAS NRAS BRAF MSI-H dMMR CRC 2021.09.01 2022.10.09 HCC/2022.11.07 PD-L1 CPS 20 TNBC 2021.08.03 r/r r/r cHL 2023.01.13 2021.08.25 MSI-H 2022.03.25 MSI-H 2022.10.31 sqNSCLC 2023.01.17(ES-SCLC)PD-1 2/2*10PD-L1 02 PD-L1 2020.02.10 ES-SCLC 2020.10.29 2021.04.29 50%PD-L1 PD-L1 IC 10%EGFR ALK NSCLC 2021.06.22 EGFR ALK NSCLC 2022.03.18 1%TC PD-L1 II-IIIA*2019.12.06 III NSCLC 2021.07.19()(ES-SCLC)MSI-H dMMR 2021.11.25 MSI-H dMMR/MSI-H dMMR 2022.07.19 MSI-H dMMR 2022.09.29 2021.12.21 EGFR ALK*2022.06.02 III NSCLC 2023.03.03 ES-SCLC PD-L1*PD-1/PD-L1 ADC 03.11*12 PD-1/PD-L1 III 03 PD-1/PD-L1 PD-1/PD-L1 III Phase III 402()2018-12-06 Phase III 406()2019-11-06 Phase III 500()2021-04-27 Phase III 1210()2021-11-30 Phase III 581()2020-08-03 Phase III 674()2020-12-08/Phase III 162 2022-06-15/Phase III 37 2019-12-28/Phase III 1440()2021-11-12 Phase III()2023-04-20 Phase III()2023-04-21/Phase III 480()2023-01-09 PD-1 III*13PD-1/PD-L1 ADC K 03 PD-1/PD-L1 ADC ADC ADC MSD Enfortumab Vedotin Nectin-4 Phase III 794()2021-12-31Enfortumab Vedotin Nectin-4 Phase III 840()2022-05-16Enfortumab Vedotin Nectin-4 Phase III 860 2023-03-15Enfortumab Vedotin Nectin-4 Phase III 1150()2023-03-22Dato-DXd TROP2 Phase III 852()2022-04-22Dato-DXd TROP2 Phase III 1123()2023-01-19Sacituzumab Govitecan TROP2 Phase III 706()2023-01-06SKB264 TROP2 Phase II 264()2022-12-30SKB264 TROP2 Phase II 474()2023-03-17 HER2 Phase III 304()2021-12-06 HER2 Phase II 30 2022-08-18 HER2 HER2 Phase III 1705()2021-06-02 Dato-DXd TROP2 Phase III 1236()2023-03-06Dato-DXd TROP2 Phase III 1150()2023-03-22 HER2 HER2+Phase Ib/II 270()2021-12-31 PD-1/PD-L1 ADC*14PD-1/PD-L1 ADC 03 PD-1/PD-L1 ADC ADC ADC HER2 Phase III 452()2022-03-03 HER2 HER2 Phase II 160()2023-05-17 HER2 Phase II 40()2022-02-25RC108 c-Met Phase I/II 106()2023-04-23RC88 MSLN Phase I 72()2023-03-23LM-302 CLDN18.2 Phase II()2023-05-12ARX788 HER2 HER2 Phase I 120()2022-09-09 IBI126 CEA Phase II 130()2023-04-21 HER2 Phase II 12 2022-01-08 HER2 Phase II 45 2023-01-29 HER2 Phase II 31 2022-09-19 FS-1502 HER2 Phase II()2022-09-01 SHR-A1921 TROP2 Phase Ib/II 120()2023-02-17SHR-A1811 HER2 Phase Ib/II 324()2022-07-27SHR-A1811 HER2 HER2 Phase Ib/II 402()2022-04-26 MRG003 EGFR Phase I/II 156()2022-05-16MRG002 HER2 HER2 Phase I/II 30()2022-03-11 PD-1/PD-L1 ADC*15PD-1/PD-L1 ADC 03 PD-1/PD-L1 PD-1/PD-L1 ADC ADC KL-A167SKB264 TROP2 Phase II 95()2022-07-12SKB264 TROP2 Phase II 110()2022-05-05 BAT1306BAT8001 HER2 HER2 Phase Ib/IIa 42()2019-04-08BAT8001 HER2 HER2 Phase Ib/IIa 39 2019-04-03 SHR-1701 SHR-A1811 HER2 HER2 Phase Ib/II 156()2023-01-06 RC98 HER2;Phase I 24()2022-07-15 PD-1/PD-L1 ADC*16PD-1/PD-L1 ADC 03 2020 PD-1/PD-L1 ADC PD-1/PD-L1 PD-1 ADC()NCT04230109;II 51 2020-01-18 2025-10-01 NCT04700124/III 784 2021-01-07 2026-12-23 NCT04873362;HER2 III 1700 2021-05-05 2025-12-18 Dato-DXd NCT05061550/II 350 2021-09-29 2026-03-30 NCT05480384;II 25 2022-07-29 2025-01-01 NCT05488353;IV 48 2022-08-04 2026-04-30 Dato-DXd NCT05629585;III 1075 2022-11-29 2027-09-20 NCT05633654 III 1514 2022-12-01 2027-07-01 NCT05675579;II 25 2023-01-09 2024-03-29 NCT05726175;HER2 II 20 2023-02-13 2024-07-31 NCT05775471;II 21 2023-03-20 2026-01-01 NCT05795101;HER2 II 63 2023-04-03 2027-12-01 NCT05837806 II 27 2023-05-01 2024-11-30 PD-1/PD-L1 ADC*04.17*18 04 PD-1*THANKS 8 1 5F 200120 28 A 18 100005 6001 32 05 518026 S0100523050002 S0100123050028 19*12 A 300 500 15%5%15%-5%5%5%5%-5%5%5%*20
展开阅读全文